Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats.
Previous studies suggest that activation of the CNS melanocortin system reduces appetite while increasing sympathetic activity and arterial pressure. The present study tested whether endogenous activity of the CNS melanocortin 3/4 receptors (MC3/4-R) contributes to elevated arterial pressure in the spontaneously hypertensive rat (SHR), a model of hypertension with increased sympathetic activity. A cannula was placed in the lateral ventricle of male SHR and Wistar (WKY) rats for chronic intracerebroventricular (ICV) infusions (0.5 muL/h). Mean arterial pressure (MAP) and heart rate (HR) were recorded 24 hour/d using telemetry. After 5-day control period, rats were infused with MC3/4-R antagonist (SHU-9119, 1 nmol/h-ICV) for 12 days, followed by 5-day posttreatment period. MC3/4-R antagonism increased food intake in SHR by 90% and in WKY by 125%, resulting in marked weight gain, insulin resistance, and hyperleptinemia in SHR and WKY. Despite weight gain, MC3/4-R antagonism reduced HR in SHR and WKY ( approximately 40 bpm), while lowering MAP to a greater extent in SHR (-22+/-4 mm Hg) than WKY (-4+/-3 mm Hg). SHU9119 treatment failed to cause further reductions in MAP during chronic adrenergic blockade with propranolol and terazosin. These results suggest that endogenous activity of the CNS melanocortin system contributes to the maintenance of adrenergic tone and elevated arterial pressure in SHR even though mRNA levels for POMC and MC4R in the mediobasal hypothalamus were not increased compared to WKY. These results also support the hypothesis that weight gain does not raise arterial pressure in the absence of a functional MC3/4-R.
da Silva
Alexandre A
AA
Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State St, Jackson, MS 39216-4505, USA. asilva@physiology.umsmed.edu
do Carmo
Jussara M
JM
Kanyicska
Bela
B
Dubinion
John
J
Brandon
Elizabeth
E
Hall
John E
JE
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D054369:Agouti-Related Protein / Q000235:genetics; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006977:Hypertension, Renal / Q000188:drug therapy / Q000503:physiopathology*; D007031:Hypothalamus / Q000502:physiology; D008297:Male; D053486:Melanocortins / Q000378:metabolism; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology; D009478:Neuropeptide Y / Q000235:genetics; D011224:Prazosin / Q000031:analogs & derivatives / Q000494:pharmacology; D011333:Pro-Opiomelanocortin / Q000235:genetics; D011433:Propranolol / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D044104:Receptor, Melanocortin, Type 3 / Q000037:antagonists & inhibitors / Q000235:genetics*; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors / Q000235:genetics*; D054411:Receptors, Leptin / Q000235:genetics; D013564:Sympathetic Nervous System / Q000502:physiology*
C515197:AGRP protein, rat; D000317:Adrenergic alpha-Antagonists; D054369:Agouti-Related Protein; D000959:Antihypertensive Agents; D053486:Melanocortins; D009478:Neuropeptide Y; D012333:RNA, Messenger; D044104:Receptor, Melanocortin, Type 3; D044105:Receptor, Melanocortin, Type 4; D054411:Receptors, Leptin; C103272:SHU 9119; D011333:Pro-Opiomelanocortin; C041226:Terazosin; D009074:Melanocyte-Stimulating Hormones; D011433:Propranolol; D011224:Prazosin